Drug Profile
Campylobacter vaccine - Acambis
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Acambis
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Campylobacter infections
Most Recent Events
- 25 Sep 2008 Acambis has been acquired by sanofi pasteur
- 12 May 2004 Suspended - Preclinical for Campylobacter infections in United Kingdom (unspecified route)
- 05 Feb 2004 The campylobacter vaccine is available for licensing (http://www.acambis.com)